Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is also developing two discovery-stage programs for chronic pain and hearing disorders, both targeting the nicotinic acetylcholine receptor (nAChR). These programs have shown strong pre-clinical data, and if successful in clinical trials, could diversify the company's portfolio and increase its market potential. Moreover, the company operates in the United States, a leading market for pharmaceuticals, providing access to a large patient population and potential for growth.

Bears say

Rapport Therapeutics is a clinical-stage biotechnology company with a portfolio of programs designed to target neurological and psychiatric disorders. With a lead asset in RAP-219, the company has a potential treatment for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. However, the company's reliance on a single asset and the competitive landscape of the psychiatric drug market raise concerns about its long-term success. Additionally, there are uncertainties around the extent of RAP-219's clinical benefit and the potential for side effects, as well as the company's financial stability with a low cash balance and limited revenue at this stage of development.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.